Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine
Open Access
- 2 December 2021
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 160 (2) , 172-184
Abstract
The prevention of tau protein aggregations is a therapeutic goal for the treatment of Alzheimer's disease (AD), and hydromethylthionine (HMT) (also known as leucomethylthioninium‐mesylate [LMTM]), is a potent inhibitor of tau aggregation in vitro and in vivo. In two Phase 3 clinical trials in AD, HMT had greater pharmacological activity on clinical endpoints in patients not receiving approved symptomatic treatments for AD (acetylcholinesterase (AChE) inhibitors and/or memantine) despite different mechanisms of action. To investigate this drug interaction in an animal model, we used tau‐transgenic L1 and wild‐type NMRI mice treated with rivastigmine or memantine prior to adding HMT, and measured changes in hippocampal acetylcholine (ACh) by microdialysis. HMT given alone doubled hippocampal ACh levels in both mouse lines and increased stimulated ACh release induced by exploration of the open field or by infusion of scopolamine. Rivastigmine increased ACh release in both mouse lines, whereas memantine was more active in tau‐transgenic L1 mice. Importantly, our study revealed a negative interaction between HMT and symptomatic AD drugs: the HMT effect was completely eliminated in mice that had been pre‐treated with either rivastigmine or memantine. Rivastigmine was found to inhibit AChE, whereas HMT and memantine had no effects on AChE or on choline acetyltransferase (ChAT). The interactions observed in this study demonstrate that HMT enhances cholinergic activity in mouse brain by a mechanism of action unrelated to AChE inhibition. Our findings establish that the drug interaction that was first observed clinically has a neuropharmacological basis and is not restricted to animals with tau aggregation pathology. Given the importance of the cholinergic system for memory function, the potential for commonly used AD drugs to interfere with the treatment effects of disease‐modifying drugs needs to be taken into account in the design of clinical trials. imageKeywords
This publication has 38 references indexed in Scilit:
- Progression of Tau Pathology in Cholinergic Basal Forebrain Neurons in Mild Cognitive Impairment and Alzheimer's DiseaseThe American Journal of Pathology, 2011
- Cellular and molecular actions of Methylene Blue in the nervous systemMedicinal Research Reviews, 2010
- Neurotransmitters and Energy Metabolites in Amyloid-Bearing APPSWE×PSEN1dE9 Mouse BrainThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer DiseaseJournal of Neuropathology & Experimental Neurology, 2008
- The role of acetylcholine in learning and memoryCurrent Opinion in Neurobiology, 2006
- Cortical load of PHF-tau in Alzheimer's disease is correlated to cholinergic dysfunctionJournal of Neural Transmission, 1999
- The interaction between methylene blue and the cholinergic systemBritish Journal of Pharmacology, 1997
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Loss of M2 Muscarine Receptors in the Cerebral Cortex in Alzheimer's Disease and Experimental Cholinergic DenervationScience, 1985
- Methylene Blue as an Inhibitor of Acetylcholin-Esterase.Acta Chemica Scandinavica, 1950